Geron Corporation's RYTELO gains FDA approval for Low-Risk MDS, with strong sales projections and promising Phase 3 study.

A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that ...

The single-center report showed the therapy had a favorable safety profile and manageable side effects in children with relapsed or refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic ...

The study highlights poor outcomes for leukaemia patients with a history of myelodysplastic syndrome treatment and related ...

Vevoctadekin is under clinical development by Simcha Therapeutics and currently in Phase I for Myelodysplastic Syndrome.

Trecondyv is under clinical development by medac and currently in Pre-Registration for Myelodysplastic Syndrome.

Panelists discuss key learnings from recent studies on lower-risk myelodysplastic syndrome (LR-MDS) treatment, identify ...

The FDA granted Rigel Pharmaceuticals (RIGL) orphan status for its treatment of myelodysplastic syndromes.Stay Ahead of the Market:Discover ...

Rigel Pharmaceuticals (RIGL) announced the FDA has granted Orphan Drug designation to R289 for the treatment of myelodysplastic ...

R289 has gained orphan drug status from the FDA for the treatment of patients with myelodysplastic syndromes. The FDA has ...